Verve Therapeutics is fully owned and operated as a wholly-owned subsidiary of the major global pharmaceutical enterprise Eli Lilly and Company. Before being acquired through a friendly tender offer and definitive merger agreement, Verve operated independently as a publicly traded entity on the Nasdaq exchange. Now integrated under Eli Lilly's broad corporate umbrella, its research laboratories, clinical pipelines, and scientific personnel operate as part of Lilly's specialized cardiometabolic research and development division.